Company / EPS (Diluted)
United Therapeutics EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$19.81
FY2025
5-year range
-$2.39 / $19.81
FY2021-FY2025
Trend
+32.1%
vs FY2024
Sector context
#3 of 204
Health Care
What the data says
Among 204 Health Care companies, United Therapeutics is in the top 1% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-2.39 in FY2021 to $19.81 in FY2025.
Based on SEC 10-K filings.
19.81 in FY2025 with a 5-year CAGR of +8.1%. Ranks 3rd among 204 companies in Health Care.
Improved from $10.06 to $19.81 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +19.7%
- 5-Year CAGR
- +8.1%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 204This company $19.81 Sector average -$0.89
▼
+2335.3% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 32.1% year-over-year.
- Ranks #3 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.81 | +32.1% |
| FY2024 | $15.00 | +49.1% |
| FY2023 | $10.06 | -12.8% |
| FY2022 | $11.54 | +582.8% |
| FY2021 | -$2.39 | -117.8% |
| FY2020 | $13.39 | +43.8% |
| FY2019 | $9.31 | -39.0% |
| FY2018 | $15.25 | +19.9% |
| FY2017 | $12.72 | +102.5% |
| FY2016 | $6.28 | +91.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026